Halozyme Therapeutics
HALO
$33.57
Share price
3.32%
Change (1 day)
-24.48%
Change (1 year)
Categories
Halozyme Therapeutics (HALO) - Total debt
Total debt on the balance sheet as of December 2022 : $1.50 B
According to Halozyme Therapeutics's latest financial reports the company's total debt is $1.50 B. A company’s total debt is the sum of all current and non-current debts.
Halozyme Therapeutics - Total debt on balance sheet (from 2012 to 2022)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $1.50 B | 71.8% |
| 2021-12-31 | $0.87 B | 120.7% |
| 2020-12-31 | $0.39 B | -1.33% |
| 2019-12-31 | $0.40 B | 218.55% |
| 2018-12-31 | $0.12 B | -37.54% |
| 2017-12-31 | $0.20 B | -6.59% |
| 2016-12-31 | $0.21 B | 334.69% |
| 2015-12-31 | $49.83 M | -0.05% |
| 2014-12-31 | $49.86 M | 0.18% |
| 2013-12-31 | $49.77 M | 59.98% |
| 2012-12-31 | $31.11 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $39.65 B | 2,533.22% | 🇺🇸 USA |
 Pfizer PFE | $34.87 B | 2,215.25% | 🇺🇸 USA |
 Eli Lilly LLY | $18.88 B | 1,153.81% | 🇺🇸 USA |
 Sanofi SNY | $22.71 B | 1,408.37% | 🇫🇷 France |
 Baxter BAX | $16.88 B | 1,021.37% | 🇺🇸 USA |
 MannKind Corp MNKD | $0.38 B | -74.58% | 🇺🇸 USA |